Inherited variants in an androgen transporter gene may determine the time to progression (TTP) for men with prostate cancer receiving androgen deprivation therapy (ADT).
For those patients diagnosed with localized prostate cancer, the risk of recurrence is approximately 30%--even years after initial treatment.
A new study found that the androgen receptor splice variant 7 is associated with resistance to two therapies for metastatic castration-resistant prostate cancer.
The American Society of Clinical Oncology and Cancer Care Ontario released joint guidelines for treating metastatic castration-resistant prostate cancer.
Genetic variants could affect how cancer patients respond to radiation therapy. The results are based on a genome-wide analysis of the genetic variations among prostate cancer patients treated with external beam radiotherapy (EBRT).
Researchers have identified a potential biomarker that may confer inherent resistance to enzalutamide for patients with castration-resistant prostate cancer.
Androgen inhibition with enzalutamide significantly reduced the risk of disease progression and increased survival among men with previously untreated metastatic prostate cancer, according to the results of the phase III PREVAIL trial.
This slide show features pathology images of clear-cell, ductal, and mucinous prostate adenocarcinoma, as well as examples of various Gleason scores.